What Diatica Treats: Main Uses and Benefits

Diatica is commonly used across therapeutic domains where additional symptomatic support is needed, generally when discomfort is heightened. It offers supportive relief that helps patients cope more steadily with difficult episodes. Treatment for certain conditions involving nerve discomfort commonly includes medication to help maintain mobility and function.

The medication is applied in situations involving certain distressing symptoms, such as pain that creates noticeable physiological strain and symptoms of increased neurological or muscular activity. It is relevant in contexts involving heightened systemic burden, such as conditions characterized by periods of heightened symptoms (e.g., sciatica) or when symptoms become more disruptive during flare-ups.

Diatica is relevant when symptoms become temporarily overwhelming and is applied in situations requiring temporary assistance in symptom stabilization. It contributes to improved day-to-day comfort during symptomatic periods.

“The medication provides supportive relief when symptoms interfere with routine activities, assisting with maintaining functional stability during difficult episodes.”

Quick Fact: Supportive Management for Symptoms that Interfere with Daily Functioning

Regulatory References

1. NHS guidance on treatments for sciatica

Who can and cannot use Diatica?

Diatica (Gliclazide) is an antihyperglycemic agent restricted to specific patient populations as defined by regulatory labeling for the management of Type 2 Diabetes Mellitus (T2DM). The official eligibility profile strictly prohibits use in several patient groups.

---

Eligibility Scope

Category	Regulatory Status
Populations for whom use is allowed (as stated in label)	Adults with Type 2 Diabetes Mellitus (T2DM).
Populations for whom use is not recommended (if applicable)	Children and adolescents (under 18 years); Patients experiencing acute stress conditions (e.g., trauma, severe infection).
Populations for whom use is contraindicated	Patients with Type 1 Diabetes Mellitus; Patients with diabetic keto-acidosis, pre-coma, or coma; Individuals with known hypersensitivity to gliclazide, other sulfonylureas, or sulfonamides.

---

Condition-Specific Eligibility Rules

Use is contraindicated in cases of severe hepatic impairment and severe renal impairment; insulin administration is generally recommended for these conditions. The medicine is also contraindicated during pregnancy and lactation (breastfeeding). Furthermore, safety and effectiveness have not been established in the pediatric population (children and adolescents), and use in this age group is not recommended.

---

Eligibility Summary

Regulatory documents strictly define who can and cannot use this medicine by establishing a clear set of non-negotiable contraindications, primarily encompassing Type 1 diabetes and severe organ dysfunction. Eligibility is conditional on the patient being an adult with Type 2 diabetes who is not in a state of acute clinical stress or a specific physiological state, such as pregnancy or lactation.

Interactions with other medicines and products

The interaction profile of Diatica is significantly shaped by its role as a substrate for the CYP3A4 enzyme and the P-glycoprotein (P-gp) transporter. Co-administration with other medicines that affect these systems can alter the amount of Diatica in the body, potentially requiring specific clinical management.

---

Pharmacokinetic Interactions

Concomitant Medicine Category	Documented Interaction	Constraint/Requirement
Strong CYP3A4 Inhibitors	Significantly increases Diatica exposure (AUC and C max).	Requires a maximum daily dose not be exceeded.
Strong CYP3A4 Inducers	Significantly decreases Diatica exposure (AUC and C max).	Co-administration is generally not recommended due to potential loss of therapeutic effect.

---

Pharmacodynamic Interactions

Interactions not related to drug levels are also documented, primarily concerning additive effects on specific physiological functions.

Concomitant Medicine Category	Documented Interaction	Constraint/Requirement
Agents that prolong the QT interval	Predicted risk of additive QTc prolongation.	Co-administration is contraindicated.
CNS Depressant Agents	Potentiation of CNS depressant effects.	Enhanced clinical monitoring is required.

---

The regulatory labeling for Diatica establishes mandatory constraints for co-administration. These restrictions include absolute contraindications, necessary dose limitations when strong CYP3A4 inhibitors are present, and the requirement for enhanced monitoring when combined with certain pharmacodynamic drug classes. This framework is essential for safely prescribing Diatica.

The core mechanism of Gliclazide, the active molecule in Diatica, initiates at the pancreatic beta-cell membrane. The drug acts as an inhibitor by binding specifically to the Sulfonylurea Receptor 1 (SUR1), a subunit of the ATP-sensitive potassium channel ( K ATP channel). This binding prevents the normal efflux of potassium ions ( K^+), which triggers a functional depolarization of the beta-cell membrane.

The resulting change in electrical potential opens Voltage-Dependent Calcium Channels ( VDCCs). This leads to an influx of Ca^2+ ions, which serves as the molecular signal to activate the exocytosis cascade. This pathway culminates in the release of endogenous insulin into the bloodstream. Additionally, Gliclazide exhibits an extra-pancreatic action associated with the reduction of oxidative stress and the modulation of microcirculatory homeostasis within the vascular system. This mechanism is independent of its K ATP channel blockade and contributes to a change in the systemic physiological profile.

The administration of Diatica, whose active ingredient is Gliclazide, involves its use as a long-term oral treatment for Type 2 Diabetes Mellitus. The approved route of administration is oral, and the medicine is most commonly provided as a modified-release (MR) tablet.

The standard dosing schedule typically commences with a 30 mg starting dose for the MR formulation, which is then gradually adjusted under clinical guidance over intervals of at least one month based on the individual's metabolic response. The standard maximum maintenance dose for the MR formulation is 120 mg per day.

The MR tablet must be taken once daily with the first meal of the day, specifically breakfast. This precise timing and frequency are essential for maintaining the modified release of the active substance over a 24-hour period. Therefore, the tablet must be swallowed whole and must not be crushed, chewed, or divided under any circumstances.

Specific administration rules apply to certain populations. While the standard starting dose may be used, older adults and patients with mild to moderate renal impairment require caution and close monitoring during dose initiation and maintenance. If a dose is missed, the subsequent dose should not be doubled; instead, the next scheduled dose should be taken at the usual time.

Research Evidence / Overview of Studies for Diatica (Gliclazide)

This section outlines the structure of the regulatory research and scientific evidence for Diatica (Gliclazide), focusing only on what type of studies exist and what their goals were, based on information from governmental and peer-reviewed sources.

---

The Research Landscape for Type 2 Diabetes Mellitus

The majority of evidence for Diatica (Gliclazide) comes from numerous Randomized Controlled Trials (RCTs). These studies explored scenarios comparing the medicine to other treatments or a placebo, often over defined time intervals. Many of these trials were large, multi-center, international efforts. Researchers monitored participants for several years, observing the incidence of major vascular events. The evidence base also includes systematic reviews and meta-analyses, which compile and analyze findings from many individual studies. Research has also examined long-term observational settings evaluating daily-life functioning in large groups of patients.

The initial research examined core glycemic biomarkers, which are measurements used to manage Type 2 Diabetes Mellitus (T2DM). The outcomes that were measured included changes in Glycated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG) levels. Over longer timeframes, research explored outcomes related to major vascular events. These studies provide context but not individual predictions about whether an individual will respond similarly.

Long-Term Evidence and Extended Follow-up

A significant portion of the evidence comes from large-scale, long-term research, with follow-up durations extending for four to over six years in some major trials. These extended studies were aimed to monitor outcomes related to major vascular complications and overall mortality over extended time intervals. The findings describe patterns observed related to the risk of complications associated with T2DM over several years. However, long-term effects are not fully established for all possible complications, and the results apply only to the specific populations studied, meaning that the findings describe group patterns, not personal outcomes.

Research Limitations and Areas of Uncertainty

While research has explored many aspects of Diatica (Gliclazide), certain limitations and areas of uncertainty remain. Comparative evidence is lacking for direct, long-term Randomized Controlled Trials (RCTs) against some of the newer drug classes now available for T2DM, such as SGLT2 inhibitors or GLP-1 receptor agonists. Furthermore, follow-up durations were limited in many of the older head-to-head trials, which provides limited insight into long-term outcomes for comparisons with other treatments beyond the initial glycemic control phase. Subgroup findings are often uncertain, meaning that results apply only to the populations studied and do not determine whether an individual outside those groups will respond similarly.

Key Studies & References Essential Medicines List: Gliclazide

Common questions about Diatica (FAQ)

---

Q: Are there any common foods or drinks that interact with Diatica?

A: Official product information emphasizes that maintaining a regular eating schedule is important because taking Diatica can increase the risk of hypoglycemia (very low blood sugar) if meals are skipped or carbohydrate intake is irregular. Regulatory documents state that alcohol is not advisable as it can increase the blood sugar-lowering effect of the medicine.

Q: Why do some people stop taking Diatica?

A: Discontinuation of Diatica is associated with specific severe adverse reactions and contraindications outlined in regulatory documents. Factual reasons may include persistent hypoglycemia (low blood sugar), severe skin conditions, or specific liver problems like cholestatic jaundice that necessitate a change in treatment.

Q: Are there different strengths or versions of Diatica available?

A: Yes, official prescribing information indicates that Diatica (Gliclazide) is available in different formulations. These include both standard tablets and modified-release (MR) tablets, which are designed to control the release of the active substance over a longer period. Available formulations, such as the modified-release (MR) tablets, are provided in various strengths.

Q: Can people with liver disease use Diatica?

A: According to regulatory sources, Diatica is contraindicated (must not be used) in patients with severe hepatic insufficiency (severe liver disease). Regulatory guidance notes that patients with mild to moderately impaired liver function are conditions that require cautious management and close monitoring.

Q: What should I look out for when I first start taking Diatica?

A: Official safety information documents symptoms of low blood sugar, or hypoglycemia, for which patients are advised to be aware, as this is a very common side effect. Regulatory documents also note that transient visual disturbances (temporary changes in vision) are more likely to occur upon treatment initiation as blood glucose levels begin to change.

Q: Does Diatica affect blood pressure or heart rate?

A: Diatica's primary action is on blood sugar. Symptoms associated with the body’s compensatory response to low blood sugar (hypoglycemia) are documented to include tachycardia (a fast heart rate) and palpitations. These effects are generally associated with a severe drop in blood glucose.

Q: Are there any long-term side effects associated with Diatica use?

A: Regulatory documents do not strictly separate side effects into 'long-term' versus 'short-term' categories. As Diatica is indicated for long-term treatment, the documented risk of known adverse reactions, such as hypoglycemia, is continuous throughout the period of use. Clinical trials have monitored patients over extended periods for outcomes related to diabetes complications.

Q: Can Diatica affect my ability to drive or operate machinery?

A: Official product information contains a warning regarding the ability to drive or operate machines. Due to the very common risk of hypoglycemia (low blood sugar), which can cause symptoms like dizziness, drowsiness, and confusion, regulatory documents indicate that patients must be aware of hypoglycemia symptoms because the condition can impair the ability to drive or use machines.

Q: Is it normal to feel tired when starting Diatica?

A: While general fatigue is not listed as a common side effect in official reports, unusual tiredness is a documented symptom of hypoglycemia (low blood sugar). Since hypoglycemia is a very common effect, patients should be mindful of tiredness occurring alongside other signs of low blood sugar.

Q: What should I do if a side effect of Diatica feels severe?

A: Official regulatory guidance states that a severe or prolonged hypoglycaemic episode requires immediate medical treatment or hospitalization. This requirement extends to severe reactions such as severe skin rashes or specific liver problems, even if the low blood sugar is temporarily corrected.

Q: Can Diatica cause changes in mood or sleep patterns?

A: According to official documentation, changes in mood and sleep patterns are recognized as possible symptoms of hypoglycemia. Symptoms associated with low blood sugar can include sleep disorders, agitation, aggression, depression, and confusion.

Q: Are there any specific supplements that interact with Diatica?

A: Official prescribing information documents specific interactions with certain remedies. For example, the use of the herbal remedy St. John's Wort is documented to have pharmacodynamic interactions that may interfere with Diatica, potentially leading to a loss of blood glucose control or hyperglycemia (high blood sugar).

Q: Are there specific medical tests required before starting Diatica?

A: Official regulatory documents recommend that healthcare providers assess blood sugar control through laboratory tests. Measurement of glycated haemoglobin ( HbA1c) or fasting venous plasma glucose is often used to assess blood sugar control before and during treatment.

Q: Is Diatica known to cause weight gain or loss?

A: Unexpected weight gain is listed in official patient information as a potential side effect. This is related to the medicine’s pharmacological action of stimulating the release of insulin, which can lead to increased storage of glucose.

Q: Can Diatica be taken by individuals who are lactose intolerant?

A: Official drug documents indicate that some tablet formulations of Diatica (Gliclazide) contain lactose as an excipient (an inactive ingredient used to form the tablet). The presence of lactose as an excipient means individuals with documented intolerance may need to verify the excipient list provided on the product label.

How to Store and Dispose of Diatica?

The official storage profile for Diatica is strictly defined to maintain the drug's quality and stability.

Storage Conditions

• Temperature: Store Diatica at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
• Protection: Keep the medication in its original, tightly closed container to protect it from moisture and excessive heat.
• Child Safety: It must be stored out of the reach and sight of children and pets to prevent accidental exposure.

Stability and Handling

• In-Use Stability: Any unused portion of the product must be discarded 60 days after the container is first opened.
• Handling: Do not refrigerate or freeze the product unless specifically instructed by the label.

Disposal Protocol

• The preferred method for disposal of unused, unwanted, or expired Diatica is through an official drug take-back program.
• If a take-back program is unavailable, safe household disposal involves mixing the medicine with an unappealing substance, sealing it in a plastic bag, and placing it in the trash. The empty container must have all personal information removed.